<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01902329</url>
  </required_header>
  <id_info>
    <org_study_id>SGN33A-001</org_study_id>
    <nct_id>NCT01902329</nct_id>
  </id_info>
  <brief_title>A Safety Study of SGN-CD33A in AML Patients</brief_title>
  <official_title>A Phase 1 Trial of SGN-CD33A in Patients With CD33-positive Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the safety profile of vadastuximab talirine (SGN-CD33A) administered
      as a single agent and in combination with a hypomethylating agent (HMA). The main purpose of
      the study is to find the maximum tolerated dose (MTD, which is the highest dose that does not
      cause unacceptable side effects) of SGN-CD33A in patients with acute myeloid leukemia (AML).
      The MTD will be determined by observing the dose-limiting toxicities (the side effects that
      prevent further increases in dose) of SGN-CD33A. In addition, the pharmacokinetic profile and
      anti-leukemia activity of SGN-CD33A will be assessed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will explore SGN-CD33A as a monotherapy and in combination with a hypomethylating
      agent (HMA; i.e., azacitidine or decitabine). Initial study treatment with SGN-CD33A includes
      a maximum of 2 cycles of treatment for monotherapy and 4 cycles for combination cohorts.
      Patients who achieve documented CR or CRi (Monotherapy) or clinical benefit (Combination)
      during the first part of the study are eligible to continue treatment.

      Additional monotherapy cohorts may include patients with relapsed acute promyelocytic
      leukemia, relapsed patients with nucleophosmin-1 gene mutation (absence of fms-like tyrosine
      kinase 3 mutation) (NPM1-mutated, FLT-3 wild type), alternate dosing schedules (fractionated
      dosing on Days 1 and 4), treatment naive patients with AML who declined intensive therapy,
      and patients who have relapsed after post-allogeneic stem cell transplant.

      Patients in the combination cohort will be treated with azacitidine or decitabine per
      institutional practice prior to SGN-CD33A dosing. Expansion cohorts may be added for further
      evaluation of safety, pharmacokinetics, pharmacodynamics, and antitumor activity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Actual">December 8, 2017</completion_date>
  <primary_completion_date type="Actual">March 18, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Through 1 month following last dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>Through 1 month following last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Blood concentrations of SGN-CD33A and metabolites</measure>
    <time_frame>Through 3 weeks after dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of antitherapeutic antibodies</measure>
    <time_frame>Through 1 month following last dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complete remission</measure>
    <time_frame>Up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of complete remission</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse-free survival</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to approximately 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">195</enrollment>
  <condition>Acute Myelogenous Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Promyelocytic Leukemia</condition>
  <arm_group>
    <arm_group_label>SGN-CD33A + HMA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SGN-CD33A with hypomethylating agent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SGN-CD33A Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SGN-CD33A</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HMA</intervention_name>
    <description>azacitidine 75 mg/m2 for 7 days or decitabine 20mg/m2 for 5 days</description>
    <arm_group_label>SGN-CD33A + HMA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGN-CD33A</intervention_name>
    <description>Given intravenously on Day 1 or Days 1 and 4 every 3 weeks (SGN-CD33A Monotherapy) or given intravenously on the final HMA dosing day every 4 weeks (SGN-CD33A+HMA)</description>
    <arm_group_label>SGN-CD33A + HMA</arm_group_label>
    <arm_group_label>SGN-CD33A Monotherapy</arm_group_label>
    <other_name>vadastuximab talirine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Acute myeloid leukemia, positive for CD33

          -  Eastern Cooperative Oncology Group status of 0 or 1

          -  Adequate baseline renal and hepatic function

          -  Central venous access

          -  Either achieved complete remission (greater than 12 weeks in duration) with initial
             induction/consolidation and have experienced relapse of disease or declined treatment
             with high-dose induction/consolidation

          -  Bone marrow blasts greater than or equal to 5% for relapsed patients, or greater than
             or equal to 20% for untreated patients

        Exclusion Criteria:

          -  Inadequate lung function

          -  Prior allogeneic stem cell transplant, except for a specific cohort

          -  High-dose chemotherapy within 4 weeks of study drug

          -  Antileukemia treatment within 14 days of study drug (other than hydroxyurea or
             6-mercaptopurine)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phoenix Ho, MD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute / Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic, The</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charles A. Sammons Cancer Center / Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center / University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2013</study_first_submitted>
  <study_first_submitted_qc>July 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2013</study_first_posted>
  <last_update_submitted>January 3, 2018</last_update_submitted>
  <last_update_submitted_qc>January 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Antibody-Drug Conjugate</keyword>
  <keyword>CD33 Antigen</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Drug Therapy</keyword>
  <keyword>Acute Myelogenous Leukemia</keyword>
  <keyword>Acute Promyelocytic Leukemia</keyword>
  <keyword>APL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Leukemia, Promyelocytic, Acute</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

